Search Results 1661-1670 of 16203 for Epilepsy (Partial Onset)
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment.
... focal RT ≥ 4 weeks prior to study entry. if the lesion used for on-study ... unless they commit to complete abstinence beginning at least 28 days (4 ...
Rochester, Minn. The purpose o fthis study. A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia ...
Van Gompel, M.D.. Neurosurgeon. Rochester, MN. Areas of focus: Epilepsy surgery, Pituitary tumor surgery, Computer assisted brain surgery, Endoscopic procedure ...
... partial response [PR]), overall survival (OS), duration of response (DOR), time to progression (TTP). A Study of Napabucasin (BBI-608) in Combination ...
Also, to improve disease control by decreasing the number of spinal relapses for patients who achieve a complete response (CR) or partial ... epilepsy. A ...
About this study. This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and ...
Pure Motor Onset and IgM-Gammopathy Occurrence in Multifocal Acquired Demyelinating Sensory and Motor Neuropathy. Neurology. 2021 Oct 4; 97 (14):e1392-e1403 ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.